Incannex Healthcare

What Incannex Healthcare does

Incannex Healthcare is a clinical-stage biopharmaceutical company developing novel oral fixed-dose combination therapies for chronic conditions with limited treatment options. The company, founded in 2001 in Victoria, Australia and dual-listed on the ASX (IHL) and Nasdaq (IXHL), operates from Melbourne with a workforce of 11-50 employees and is led by President and CEO Joel Latham, CFO Joseph Swan, CMO Lou Barbato, M.D., and CSO Mark Bleakley, Ph.D. Its scientific approach pairs synthetic cannabinoids or psychedelic-inspired compounds with well-characterized active pharmaceutical ingredients to target multiple physiological pathways simultaneously, enabling lower per-component dosing and reduced side effects.

The pipeline comprises three drug candidates. The lead asset, IHL-42X, combines dronabinol (synthetic THC) and acetazolamide for obstructive sleep apnea, an indication with no approved pharmacologic therapy and an estimated U.S. patient population of approximately 22 million. Phase 2 data showed up to an 83% reduction in the Apnea-Hypopnea Index in the high-dose cohort, and the asset received FDA Fast Track designation in December 2025 alongside a USPTO patent grant (baseline expiry July 9, 2040). IHL-675A combines synthetic CBD and hydroxychloroquine for rheumatoid arthritis (Phase 2, 128 patients), and PSX-001 is an oral synthetic psilocybin administered with psychological support for generalized anxiety disorder (Phase 2, 94 patients), where 44% of patients achieved a 50%+ reduction in anxiety scores versus placebo.

Incannex has no commercial products and no product revenue. Its business model contemplates future commercialization of approved assets through prescription-based specialty-pharma distribution channels, supported by global clinical operations across the U.S., U.K., and Europe. To date, the company has funded operations through equity raises (cumulative approximately $25.8M across September 2024, March 2025, and March 2026) and Australian R&D tax incentives (approximately A$11.1M across FY25 and FY26). As of early 2026, the company reported approximately $75M in cash with no debt, completed a 1-for-30 reverse stock split to maintain Nasdaq compliance, and was advancing its 14-site DReAMzz crossover dose-optimization study while continuing the larger 560-patient RePOSA Phase 2/3 trial.

Name

Incannex Healthcare

Legal name

Incannex Healthcare Limited

Website

https://incannex.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Incannex Healthcare is a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies — IHL-42X for obstructive sleep apnea, IHL-675A for rheumatoid arthritis, and PSX-001 for generalized anxiety disorder — using cannabinoid- and psychedelic-inspired compounds paired with established drugs. It is pre-revenue and dual-listed on the ASX and Nasdaq.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Other Ambulatory Health Care Services (6219), Medical and Diagnostic Laboratories (62151)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Sleep, Stress & Mood Support (HLAIADAG), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Clinical-stage biopharmaceuticals
• Combination drug therapies
• Cannabinoid medicines
• Obstructive sleep apnea treatment
• Psychedelic-inspired therapeutics

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Others

Revenue model

1. Pharmaceutical product revenue (future): The company is pre-revenue and clinical-stage. Future revenue is expected from commercialization of drug candidates IHL-42X (OSA), IHL-675A (RA), and PSX-001 (GAD) following regulatory approval. No products are currently approved or commercially available.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Incannex Healthcare is a clinical-stage biopharmaceutical company developing novel oral fixed-dose combination therapies for chronic conditions. Its pipeline consists of three drug candidates: IHL-42X (dronabinol + acetazolamide) for obstructive sleep apnea, IHL-675A (cannabidiol + hydroxychloroquine) for rheumatoid arthritis, and PSX-001 (synthetic psilocybin with psychological support) for generalized anxiety disorder. The company is pre-revenue, with no products currently approved or commercially available, and is advancing candidates through Phase 2/3 trials across sites in the U.S., U.K., and Europe.

Product overview

Incannex Healthcare is a science-led combination medicines company developing three distinct drug candidates: IHL-42X (oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea), IHL-675A (oral fixed-dose combination of synthetic CBD and hydroxychloroquine sulfate for rheumatoid arthritis), and PSX-001 (oral synthetic psilocybin with psychotherapy support for generalized anxiety disorder). The company focuses on combining known active pharmaceutical ingredients to target underlying biological pathways associated with chronic conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• IHL-42X Oral fixed-dose combination therapy of acetazolamide (carbonic anhydrase inhibitor) and dronabinol (synthetic THC) designed to act synergistically, targeting two different physiological pathways associated with the intermittent hypoxia and hypercapnia that characterize obstructive sleep apnea (OSA). Intended for OSA patients who are non-compliant, intolerant, or naïve to positive airway pressure devices such as CPAP.
• IHL-675A Oral fixed-dose combination of synthetic cannabidiol (CBD) and hydroxychloroquine sulfate (HCQ) designed to target two different pathways — endocannabinoid (CB1/CB2) signaling and immune system regulation — acting synergistically to alleviate inflammation in rheumatoid arthritis.
• PSX-001 Oral synthetic psilocybin drug candidate administered in combination with psychological support (psychotherapy) for adults diagnosed with Generalized Anxiety Disorder (GAD), particularly those who do not respond adequately to first-line SSRI therapy.

Quantifiable outcome

• IHL-42X reduced AHI by up to 83% in high-dose cohort; 51% average reduction at lowest dose; 57.6% of participants perceived improvement in Phase 2 trial.
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• AASM FoundationcoreStrategic or Co-development Partner · 25 March 2026Incannex partnered with the AASM Foundation to sponsor a Focused Projects Grant for Junior Investigators dedicated to sleep apnea research. The company joined the foundation's Corporate Recognition Program to support the development of IHL-42X, its lead investigational drug for obstructive sleep apnea.
• Global Distribution Partner (Unnamed)minorChannel Partner/ Reseller/ DistributorCompany onboarded a global distribution partner for the 14-site DReAMzz crossover dose optimization study for IHL-42X. Partner assists with distribution logistics for the clinical trial program.
• Contract Research Organizations (CROs)coreImplementation/ SI/ Consulting PartnerCompany employs CRO services for dealing with clinical trial processes. CROs act as Data Processors under privacy agreements.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Eli Lilly: Large-cap pharmaceutical company with tirzepatide (Zepbound/Mounjaro) demonstrating efficacy in obstructive sleep apnea in Phase 3 trials, alongside established CNS and inflammation franchises. Comparable as a broad incumbent with overlapping OSA and inflammatory disease development programs that could compress Incannex's market opportunity.
• Jazz Pharmaceuticals: Global specialty biopharmaceutical company that acquired GW Pharmaceuticals and markets Epidiolex (cannabidiol) for seizure disorders. Comparable as a broad incumbent in cannabinoid Rx therapeutics, with established FDA registration pathways and commercial infrastructure Incannex will eventually need for IHL-675A.
• Pfizer: Global pharmaceutical company with established rheumatoid arthritis portfolio (etanercept/Enbrel and Xeljanz) and broad CNS presence. Comparable as a broad incumbent against which IHL-675A must compete in RA and that represents potential partnership or acquirer profile for clinical-stage assets like Incannex's.
• AbbVie: Global biopharmaceutical company with a market-leading rheumatoid arthritis franchise (Humira, Rinvoq, Skyrizi). Comparable as the dominant incumbent against which Incannex's IHL-675A (CBD + hydroxychloroquine) will compete for market share and pricing leverage upon potential approval.

Emerging players

• ATAI Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health disorders including anxiety and depression. Comparable to Incannex's PSX-001 psilocybin program and shares the same regulatory and reimbursement risks inherent in psychedelic-assisted therapy.
• Axsome Therapeutics: CNS-focused specialty pharmaceutical company developing therapeutics for conditions including depression and migraine. Comparable on the CNS specialty pharma commercial dynamics relevant to Incannex's PSX-001 for GAD, with similar prescriber access and payer negotiation considerations.
• Zynerba Pharmaceuticals: Clinical-stage specialty pharmaceutical company developing transdermal cannabinoid therapies for Fragile X syndrome and other neurological conditions. Comparable as a small-cap cannabinoid Rx developer with similar regulatory pathway complexity and pipeline focus.

Direct peers

• Apnimed: Clinical-stage pharmaceutical company developing oral pharmacotherapies for obstructive sleep apnea, including AD109 (a combination of atomoxetine and oxybutynin). Most directly comparable peer to IHL-42X given overlapping indication (OSA), oral combination therapy approach, and similar competitive positioning against CPAP.
• MindMed: Clinical-stage psychedelic-inspired medicine developer with a pipeline that includes LSD-based therapies for anxiety disorders. Directly comparable to Incannex's PSX-001 in targeting anxiety with psychedelic compounds, with similar regulatory and reimbursement challenges.
• Compass Pathways: Clinical-stage psychedelic medicine company developing synthetic psilocybin (COMP360) for treatment-resistant depression and other mental health conditions. Directly comparable to Incannex's PSX-001 program targeting GAD with synthetic psilocybin plus psychological support, with similar regulatory pathway and addressable market dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/asx_ihl
• LinkedInlinkedin.com/company/impressionhealthcarelimited

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Incannex Healthcare